Advertisement

Virus Genes

, Volume 54, Issue 2, pp 246–255 | Cite as

Preparation of virus-like particles for porcine circovirus type 2 by YeastFab Assembly

  • Pei Chen
  • Lei Zhang
  • Na Chang
  • Peidian Shi
  • Tian Gao
  • Lilin Zhang
  • Jinhai Huang
Article
  • 256 Downloads

Abstract

Porcine circovirus type 2 (PCV2) poses a genuine threat to pig industry. An effective vaccine production against the pandemic is desirable. The aim of this study was to construct recombination yeast strains with PCV2 Cap protein. We adopt to YeastFab Assembly method to synthesize transcriptional units in a single tube by piecing up promoter, open reading frame, and terminator in S. cerevisiae. Two yeast recombinants were successfully constructed using GPD and TEF2 promoters, respectively, to express PCV2 by secreting Cap protein in vitro. Electronic microscope observation demonstrated that the yeast-derived PCV2 Cap protein could self-assembles into 18-nm-diameter virus-like particles (VLPs). The yield of two different recombination yeasts containing GPD and TEF2 promoters were 12, 25 μg/ml, respectively. Our results showed that it is feasible to use S. cerevisiae as a safe and simple system to produce PCV2 virus-like particles. This indicated that there is possibility of obtaining PCV2 VLP vaccine by homologous recombination in yeast genome, and Cap protein was secreted into the cultural supernatant which can be used as a potential oral vaccine to protect pigs from PCV2-infection.

Keywords

Saccharomyces cerevisiae Porcine circovirus type 2 Capsid protein Virus-like particle (VLP) Vaccine 

Notes

Acknowledgements

We thank prof. Junbiao Dai of Tsinghua University for providing us the YeastFab related materials and methods. This work was supported by the National Natural Science Foundation of Youth Science Foundation in China (31400064), and the Underprop Project of Tianjin Science and Technology Committee in China (16YFZCNC00640).

Author Contributions

Conceived and designed the experiments: Jinhai Huang. Performed the experiments: Pei Chen, Tian Gao, Na Chang, Chengxue Zhao, Dong Lu, and Lilin Zhang. Analyzed the data: Lilin Zhang and Pei Chen. Contributed reagents/materials/analysis tools: Jinhai Huang. Wrote the paper: Pei Chen and Lilin Zhang.

Compliance with ethical standards

Conflict of interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

This article does not include any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in this article.

Supplementary material

11262_2018_1537_MOESM1_ESM.docx (1.3 mb)
Supplementary material 1 (DOCX 1368 kb)

References

  1. 1.
    R. Patterson et al., Oral application of freeze-dried yeast particles expressing the PCV2b Cap protein on their surface induce protection to subsequent PCV2b challenge in vivo. Vaccine 33(46), 6199–6205 (2015)CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    P. Nawagitgul et al., Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. J. Gen. Virol. 81(Pt 9), 2281–2287 (2000)CrossRefPubMedGoogle Scholar
  3. 3.
    Y. Hu et al., Evidence of natural co-infection with PCV2b subtypes in vivo. Arch. Virol. 162(7), 2015–2020 (2017)CrossRefPubMedGoogle Scholar
  4. 4.
    H. Vigre et al., Spatial and temporal patterns of pig herds diagnosed with postweaning multisystemic wasting syndrome (PMWS) during the first two years of its occurrence in Denmark. Vet. Microbiol. 110(1–2), 17–26 (2005)CrossRefPubMedGoogle Scholar
  5. 5.
    Y.F. Fu et al., Immunomodulatory and antioxidant effects of total flavonoids of Spatholobus suberectus Dunn on PCV2 infected mice. Sci Rep 7(1), 8676 (2017)CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    S. Pouyanfard, M. Muller, Human papillomavirus first and second generation vaccines-current status and future directions. Biol. Chem. 398(8), 871–889 (2017)CrossRefPubMedGoogle Scholar
  7. 7.
    H.J. Kim, H.J. Kim, Yeast as an expression system for producing virus-like particles: what factors do we need to consider? Lett. Appl. Microbiol. 64(2), 111–123 (2017)CrossRefPubMedGoogle Scholar
  8. 8.
    V. Manolova et al., Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404–1413 (2008)CrossRefPubMedGoogle Scholar
  9. 9.
    S.A. Bucarey et al., The optimized capsid gene of porcine circovirus type 2 expressed in yeast forms virus-like particles and elicits antibody responses in mice fed with recombinant yeast extracts. Vaccine 27(42), 5781–5790 (2009)CrossRefPubMedGoogle Scholar
  10. 10.
    J. Nainys et al., Generation in yeast of recombinant virus-like particles of porcine circovirus type 2 capsid protein and their use for a serologic assay and development of monoclonal antibodies. BMC Biotechnol. 14, 100 (2014)CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    G. Franzo et al., Revisiting the taxonomical classification of porcine circovirus type 2 (PCV2): still a real challenge. Virol J 12, 131 (2015)CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    B. Davies et al., Diagnostic phylogenetics reveals a new porcine circovirus 2 cluster. Virus Res. 217, 32–37 (2016)CrossRefPubMedGoogle Scholar
  13. 13.
    Y. Guo et al., YeastFab: the design and construction of standard biological parts for metabolic engineering in Saccharomyces cerevisiae. Nucleic Acids Res. 43(13), e88 (2015)CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    T. Wu et al., Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother 8(6), 823–827 (2012)CrossRefPubMedGoogle Scholar
  15. 15.
    I.H. Frazer, Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4(1), 46–54 (2004)CrossRefPubMedGoogle Scholar
  16. 16.
    W. Li et al., Genetic analysis of porcine circovirus type 2 (PCV2) strains isolated between 2001 and 2009: genotype PCV2b predominate in postweaning multisystemic wasting syndrome occurrences in eastern China. Virus Genes 40(2), 244–251 (2010)CrossRefPubMedGoogle Scholar
  17. 17.
    Q. Hou et al., Nuclear localization signal regulates porcine circovirus type 2 capsid protein nuclear export through phosphorylation. Virus Res. 246, 12–22 (2017)CrossRefPubMedGoogle Scholar
  18. 18.
    J. Lopez-Vidal et al., Improved production efficiency of virus-like particles by the baculovirus expression vector system. PLoS ONE 10(10), e0140039 (2015)CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    A.L. Hamel, L.L. Lin, G.P. Nayar, Nucleotide sequence of porcine circovirus associated with postweaning multisystemic wasting syndrome in pigs. J. Virol. 72(6), 5262–5267 (1998)PubMedCentralPubMedGoogle Scholar
  20. 20.
    H. Fan et al., Immunogenicity of empty capsids of porcine circovirus type 2 produced in insect cells. Vet. Res. Commun. 31(4), 487–496 (2007)CrossRefPubMedGoogle Scholar
  21. 21.
    S.L. Zhai et al., Complete genome characterization and phylogenetic analysis of three distinct buffalo-origin PCV2 isolates from China. Infect Genet Evol 28, 278–282 (2014)CrossRefPubMedGoogle Scholar
  22. 22.
    M.A. Ssemadaali, M. Ilha, S. Ramamoorthy, Genetic diversity of porcine circovirus type 2 and implications for detection and control. Res. Vet. Sci. 103, 179–186 (2015)CrossRefPubMedGoogle Scholar
  23. 23.
    C.T. Xiao, P.G. Halbur, T. Opriessnig, Global molecular genetic analysis of porcine circovirus type 2 (PCV2) sequences confirms the presence of four main PCV2 genotypes and reveals a rapid increase of PCV2d. J. Gen. Virol. 96(Pt 7), 1830–1841 (2015)CrossRefPubMedGoogle Scholar
  24. 24.
    F. Pitoiset, T. Vazquez, B. Bellier, Enveloped virus-like particle platforms: vaccines of the future? Expert Rev Vaccines 14(7), 913–915 (2015)CrossRefPubMedGoogle Scholar
  25. 25.
    P. Nawagitgul et al., Modified indirect porcine circovirus (PCV) type 2-based and recombinant capsid protein (ORF2)-based enzyme-linked immunosorbent assays for detection of antibodies to PCV. Clin. Diagn. Lab. Immunol. 9(1), 33–40 (2002)PubMedCentralPubMedGoogle Scholar
  26. 26.
    J.Y. Zhou et al., In vitro expression, monoclonal antibody and bioactivity for capsid protein of porcine circovirus type II without nuclear localization signal. J. Biotechnol. 118(2), 201–211 (2005)CrossRefPubMedGoogle Scholar
  27. 27.
    Z. Marcekova et al., Heterologous expression of full-length capsid protein of porcine circovirus 2 in Escherichia coli and its potential use for detection of antibodies. J. Virol. Methods 162(1–2), 133–141 (2009)CrossRefPubMedGoogle Scholar
  28. 28.
    K. Wang et al., Expression of the capsid protein of porcine circovirus type 2 in Lactococcus lactis for oral vaccination. J. Virol. Methods 150(1–2), 1–6 (2008)PubMedGoogle Scholar
  29. 29.
    M. Trundova, V. Celer, Expression of porcine circovirus 2 ORF2 gene requires codon optimized E. coli cells. Virus Genes 34(2), 199–204 (2007)CrossRefPubMedGoogle Scholar
  30. 30.
    P.C. Wu et al., Efficient expression and purification of porcine circovirus type 2 virus-like particles in Escherichia coli. J. Biotechnol. 220, 78–85 (2016)CrossRefPubMedGoogle Scholar
  31. 31.
    A. Cid-Arregui, V. Juarez, H. zur Hausen, A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J. Virol. 77(8), 4928–4937 (2003)CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    C. Engler, R. Kandzia, S. Marillonnet, A one pot, one step, precision cloning method with high throughput capability. PLoS ONE 3(11), e3647 (2008)CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Pei Chen
    • 1
  • Lei Zhang
    • 1
  • Na Chang
    • 1
  • Peidian Shi
    • 1
  • Tian Gao
    • 1
  • Lilin Zhang
    • 1
  • Jinhai Huang
    • 1
  1. 1.School of Life SciencesTianjin UniversityTianjinChina

Personalised recommendations